Literature DB >> 30887659

Vitronectin deficiency attenuates hepatic fibrosis in a non-alcoholic steatohepatitis-induced mouse model.

Momoka Hayashida1,2, Kei Hashimoto2,3, Tomoko Ishikawa2, Yasunori Miyamoto1,2.   

Abstract

Vitronectin (VN), an extracellular matrix protein, is a promising immune biomarker of non-alcoholic steatohepatitis (NASH); however, its precise function remains unclear. This study investigated how VN deficiency contributes to the development of NASH. Towards this aim, wild-type (WT) and VN-/- mice were fed with a choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD) for 6 and 10 weeks to induce NASH, and the livers were isolated. In WT mice fed with CDAHFD for 6 and 10 weeks, the expression of Vn mRNA and protein was up-regulated compared with that in mice fed with the MF control diet, indicating that VN is regulated in NASH condition. VN-/- mice showed decreased picrosirius red staining in the liver area and Col1a2 mRNA expression levels, compared with WT mice, indicating that the severity of hepatic fibrosis is attenuated in the CDAHFD-fed VN-/- mice. In addition, VN deficiency did not affect the area of lipid droplets in haematoxylin-eosin staining and the mRNA expression levels of fatty acid synthases, Srebp, Acc and Fas in the CDAHFD-fed mice. Moreover, VN deficiency decreased the inflammation score and the mRNA expression levels of Cd11b and F4/80, macrophage markers, as well as Tnf-α and Il-1β, inflammatory cytokines in the CDAHFD-fed mice. Furthermore, VN deficiency decreased the protein and mRNA expression levels of α-smooth muscle actin in the CDAHFD-fed mice, suggesting that VN deficiency inhibits the activation of hepatic stellate cells (HSCs). Our findings indicate that VN contributes to the development of fibrosis in the NASH model mice via modulation of the inflammatory reaction and activation of HSCs.
© 2019 The Authors. International Journal of Experimental Pathology © 2019 International Journal of Experimental Pathology.

Entities:  

Keywords:  hepatic fibrosis; hepatic stellate cell; inflammation; non-alcoholic steatohepatitis; vitronectin

Mesh:

Substances:

Year:  2019        PMID: 30887659      PMCID: PMC6540715          DOI: 10.1111/iep.12306

Source DB:  PubMed          Journal:  Int J Exp Pathol        ISSN: 0959-9673            Impact factor:   1.925


  36 in total

Review 1.  Cytokine regulation of hepatic stellate cells in liver fibrosis.

Authors:  H Tsukamoto
Journal:  Alcohol Clin Exp Res       Date:  1999-05       Impact factor: 3.455

2.  Engagement of alphavbeta3 integrin regulates proliferation and apoptosis of hepatic stellate cells.

Authors:  Xiaoying Zhou; Frank R Murphy; Nitu Gehdu; Junlong Zhang; John P Iredale; R Christopher Benyon
Journal:  J Biol Chem       Date:  2004-03-24       Impact factor: 5.157

3.  αvβ5 integrin mediates the effect of vitronectin on the initial stage of differentiation in mouse cerebellar granule cell precursors.

Authors:  Ayaka Abe; Kei Hashimoto; Ayumi Akiyama; Momoe Iida; Natsumi Ikeda; Ayana Hamano; Riho Watanabe; Yokichi Hayashi; Yasunori Miyamoto
Journal:  Brain Res       Date:  2018-04-24       Impact factor: 3.252

4.  Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings.

Authors:  Elizabeth M Brunt; David E Kleiner; Laura A Wilson; Patricia Belt; Brent A Neuschwander-Tetri
Journal:  Hepatology       Date:  2011-02-11       Impact factor: 17.425

5.  Intact vitronectin induces matrix metalloproteinase-2 and tissue inhibitor of metalloproteinases-2 expression and enhanced cellular invasion by melanoma cells.

Authors:  L M Bafetti; T N Young; Y Itoh; M S Stack
Journal:  J Biol Chem       Date:  1998-01-02       Impact factor: 5.157

6.  Detection of vitronectin mRNA in tissues and cells of the mouse.

Authors:  D Seiffert; M Keeton; Y Eguchi; M Sawdey; D J Loskutoff
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-01       Impact factor: 11.205

7.  Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization.

Authors:  M Crisby; G Nordin-Fredriksson; P K Shah; J Yano; J Zhu; J Nilsson
Journal:  Circulation       Date:  2001-02-20       Impact factor: 29.690

8.  Vitronectin Regulates the Fibrinolytic System during the Repair of Cerebral Cortex in Stab-Wounded Mice.

Authors:  Kei Hashimoto; Natsumi Ikeda; Mari Nakashima; Hiroko Ikeshima-Kataoka; Yasunori Miyamoto
Journal:  J Neurotrauma       Date:  2017-08-07       Impact factor: 5.269

9.  Role of endogenous opioids in modulating HSC activity in vitro and liver fibrosis in vivo.

Authors:  S De Minicis; C Candelaresi; M Marzioni; S Saccomano; T Roskams; A Casini; A Risaliti; R Salzano; N Cautero; F di Francesco; A Benedetti; G Svegliati-Baroni
Journal:  Gut       Date:  2007-11-07       Impact factor: 23.059

10.  Pharmacological inhibition of integrin alphavbeta3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis.

Authors:  Eleonora Patsenker; Yury Popov; Felix Stickel; Vreni Schneider; Monika Ledermann; Hans Sägesser; Gerald Niedobitek; Simon L Goodman; Detlef Schuppan
Journal:  Hepatology       Date:  2009-11       Impact factor: 17.425

View more
  3 in total

1.  Vitronectin deficiency attenuates hepatic fibrosis in a non-alcoholic steatohepatitis-induced mouse model.

Authors:  Momoka Hayashida; Kei Hashimoto; Tomoko Ishikawa; Yasunori Miyamoto
Journal:  Int J Exp Pathol       Date:  2019-03-18       Impact factor: 1.925

2.  Modulation of αVβ6 integrin in osteoarthritis-related synovitis and the interaction with VTN(381-397 a.a.) competing for TGF-β1 activation.

Authors:  Michel G Malaise; Dominique de Seny; Federica Ciregia; Céline Deroyer; Gaël Cobraiville; Zelda Plener; Olivier Malaise; Philippe Gillet; Marianne Fillet
Journal:  Exp Mol Med       Date:  2021-02-01       Impact factor: 8.718

3.  Urinary exosomal vitronectin predicts vesicoureteral reflux in patients with neurogenic bladders and spinal cord injuries.

Authors:  Jue Li; Shiying Cai; Chunxian Zeng; Ling Chen; Chun Zhao; Ying Huang; Wenzhi Cai
Journal:  Exp Ther Med       Date:  2021-11-23       Impact factor: 2.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.